Innovative finance can boost global health R&D

Wednesday, July 10, 2013

Whatever the exact numbers, few would dispute that only a small fraction of health R&D funding targets conditions in poor countries that account for most of the global disease burden.

This is hardly surprising, given that markets in these countries have historically been unable to deliver sufficient financial returns to support the commercial development of health solutions for neglected diseases.

To help meet the most urgent health needs of developing countries, the Bill & Melinda Gates Foundation is employing a range of innovative financing strategies that we believe can help markets ease the bottlenecks at various stages of the discovery, development, and delivery lifecycle of new medical products.

Source: Thomson Reuters Foundation (link opens in a new window)

Health Care